My Cat Has FIP: What Can I Do? Treatment Options, GS-441524, Remdesivir, and Recovery
- Vet. Doğukan Yiğit ÜNLÜ
- 16 hours ago
- 19 min read
Is FIP Still Fatal, or Can Cats Recover With Treatment?
FIP was once considered almost invariably fatal, but this is no longer an accurate description. Antiviral drugs—particularly GS-441524 and its prodrug remdesivir—can suppress viral replication and allow many affected cats to make a full recovery. Cats successfully treated for FIP may go on to live normal, healthy lives.
Treatment success depends on several factors, including how quickly therapy begins, the cat’s general condition and whether the brain, spinal cord or eyes are involved. Wet FIP may progress rapidly because fluid can accumulate in the abdomen or chest, but many cats respond well when effective antiviral therapy is started promptly. Neurological and ocular FIP are generally more difficult to treat because adequate drug concentrations must reach the nervous system or eyes.
Antiviral treatment is not guaranteed to work in every case. Severe organ failure, delayed treatment, an incorrect diagnosis, inadequate dosing, unreliable medication or failure to adjust the dose as a kitten gains weight can reduce the chance of recovery. Nevertheless, an FIP diagnosis should no longer automatically be viewed as a reason to give up.
GS-441524 is not licensed as a veterinary medicine in every country, but veterinarian-prescribed preparations are now accessible through regulated pathways in some regions. The Cornell Feline Health Center describes it as an effective treatment supported by clinical trials, while the FDA permits patient-specific compounding under defined conditions in the United States.
What Should You Do Immediately After an FIP Diagnosis?
Contact a veterinarian experienced in FIP treatment as soon as possible. Ask whether the diagnosis is sufficiently supported, which clinical form is present and whether legally obtainable GS-441524 or remdesivir is available. Because untreated FIP can progress quickly, especially when fluid is affecting breathing, treatment decisions should not be unnecessarily delayed.
The initial assessment should generally include:
An accurate body-weight measurement
Complete blood count and serum biochemistry
Albumin, globulin, A/G ratio, bilirubin and kidney values
Examination and analysis of abdominal or chest fluid when present
Assessment for eye or neurological involvement
Evaluation of hydration, appetite, temperature and breathing
Appropriate imaging or additional diagnostic testing when needed
A cat with laboured breathing, open-mouth breathing, collapse, seizures, severe weakness, inability to eat or drink, marked jaundice or very low body temperature requires emergency veterinary care. Pleural fluid that restricts breathing may need to be drained urgently. Abdominal fluid is not routinely removed solely to reduce abdominal size because rapid or excessive drainage may worsen circulation and protein loss.
If antiviral treatment is prescribed, record the cat’s starting weight, medication concentration, calculated dose and administration schedule. Kittens should be weighed frequently because successful treatment often produces rapid growth, and a dose that is not adjusted for increasing body weight can become inadequate.
Owners should avoid delaying effective treatment while trying supplements, immune boosters or home remedies. They should also avoid unlabelled medications from unknown sources, as the actual ingredient, concentration and sterility may be uncertain. Supportive care is valuable, but it cannot replace an effective antiviral drug.
How Certain Should the FIP Diagnosis Be Before Starting Treatment?
There is no single blood test that can confirm every case of FIP. Diagnosis is usually based on the cat’s age, clinical signs, imaging findings, blood results and analysis of abdominal or chest fluid. The diagnostic approach is explained more broadly in VetSaglik’s existing guide to FIP in cats.
A low albumin-to-globulin ratio, anaemia, lymphopenia, increased bilirubin and persistent fever may support the diagnosis, but none is specific to FIP. A positive feline coronavirus antibody test only confirms exposure to FCoV; it does not prove that the cat has developed FIP. Likewise, detecting coronavirus in blood or faeces is not sufficient on its own.
When effusion is present, sampling the fluid is often the most useful diagnostic step. Its colour, consistency, protein content and cellular composition can increase or decrease suspicion. FCoV RT-PCR or viral antigen testing performed on the effusion may provide stronger evidence than testing blood or faeces, although false-negative and false-positive results remain possible.
Non-effusive, ocular and neurological cases are more difficult to confirm. Ultrasound-guided sampling of affected organs or lymph nodes, cerebrospinal fluid analysis, eye examination and tissue testing may be required. Immunohistochemistry demonstrating coronavirus antigen inside macrophages within characteristic lesions remains one of the strongest methods of confirmation.
Other diseases must be excluded because lymphoma, liver disease, bacterial infections, toxoplasmosis and feline panleukopenia can produce overlapping findings. An incorrect diagnosis may delay the treatment of a different life-threatening condition.
Ideally, appropriate samples should be collected before antiviral therapy begins. However, a critically ill cat with a strongly supported FIP diagnosis may deteriorate while waiting for every test result. In such cases, a veterinarian may begin treatment while completing the diagnostic investigation. A rapid clinical response can support the diagnosis, but response to treatment should not be used as the only proof of FIP.
How Do Wet, Dry, Ocular, and Neurological FIP Affect Treatment?
Wet, dry, ocular and neurological FIP are not completely separate diseases. They represent different patterns of the same systemic infection, and a cat may have overlapping signs or transition from one presentation to another. The clinical form matters because it influences treatment intensity, monitoring and prognosis.
Wet FIP causes protein-rich fluid to collect in the abdomen, chest or occasionally around the heart. It can progress rapidly, particularly in kittens. Despite its dramatic appearance, many cats with wet FIP respond quickly to appropriate antiviral therapy when severe respiratory compromise or irreversible organ damage has not developed.
Dry FIP produces inflammatory lesions in organs such as the kidneys, liver, intestines and lymph nodes without obvious large-volume effusion. Because its signs are less specific, diagnosis is often delayed. Antiviral treatment can still be highly effective, but response must be assessed through clinical improvement, laboratory changes and repeat imaging.
Ocular FIP can cause uveitis, cloudiness, colour changes within the eye, abnormal pupils or reduced vision. Drug penetration into the eyes may be more difficult, so the veterinarian may select a more intensive antiviral protocol. Eye examinations are necessary during treatment because systemic improvement does not always mean that ocular inflammation has fully resolved.
Neurological FIP may cause an unsteady gait, tremors, head tilt, weakness, seizures, behavioural changes or paralysis. It generally requires higher antiviral exposure because the medication must cross the blood–brain barrier. Neurological cases can recover, but treatment failure and relapse are more likely if the protocol is insufficient for nervous-system involvement.
A cat initially classified as having wet or dry FIP should therefore be repeatedly checked for eye and neurological abnormalities. Discovering these signs later may require the treatment plan to be revised rather than simply continuing the original protocol unchanged.
What Is GS-441524, and How Does It Treat FIP?
GS-441524 is a nucleoside analogue antiviral that directly interferes with the replication of feline coronavirus. It is closely related to remdesivir and targets the viral RNA-dependent RNA polymerase—the enzyme the virus needs to copy its genetic material. This prevents further viral replication and allows the cat’s immune system to control the inflammation associated with FIP in cats.
GS-441524 is not an antibiotic, corticosteroid, immune booster or medication that merely masks symptoms. It acts against the underlying viral process. It cannot immediately reverse severe organ damage that has already occurred, which is why beginning effective treatment before irreversible complications develop is important.
The medication may be administered orally or by injection, depending on the available product and the cat’s condition. Oral treatment is often preferred when the cat can swallow and absorb medication reliably. Severely ill cats that cannot eat, are repeatedly vomiting or have impaired intestinal absorption may initially require an injectable antiviral under veterinary supervision.
Clinical improvement is frequently noticeable within the first several days. Fever may resolve, appetite and activity may improve, and accumulated fluid may gradually decrease. However, an early response does not mean treatment is complete. Stopping therapy when the cat begins to look better can allow the infection to return.
A landmark clinical study found GS-441524 to be effective for naturally occurring FIP, including effusive and non-effusive presentations. Twenty-four of the 31 enrolled cats ultimately achieved sustained recovery, although several required retreatment at a higher dose after relapse.
Product quality is crucial. The amount of GS-441524 stated on an unregulated label may not match the actual concentration, and contamination or poor formulation can affect safety and absorption. Wherever possible, treatment should use a legally obtainable, veterinarian-prescribed preparation from a regulated pharmacy.
Is GS-441524 Effective for Wet FIP in Kittens?
Yes. Wet or effusive FIP often looks devastating, but it is one of the presentations that can respond rapidly to GS-441524. Antiviral therapy can stop continued viral replication and inflammation, allowing fluid in the abdomen or chest to be gradually reabsorbed.
Recent clinical evidence is encouraging. In a prospective study of cats with effusive FIP, 38 of 40 cats recovered after receiving pharmacy-prepared oral GS-441524; the two deaths occurred during treatment in severely affected cats. The study also found strong outcomes in both the 42-day and conventional 84-day groups, although shorter treatment should only be considered under a veterinarian-led protocol with defined monitoring criteria.
Kittens may have a good chance of recovery when treatment starts before severe respiratory distress, shock or irreversible organ failure develops. However, they can deteriorate rapidly and should not be monitored at home for several days while owners search for medication. A kitten with difficult breathing, collapse, hypothermia or inability to eat requires immediate stabilisation and antiviral assessment.
Body weight must be measured at least weekly during treatment. A recovering kitten may gain weight quickly, causing the original milligram dose to become too low even though the same number of tablets is still being given. Dose calculations must therefore be reviewed as the kitten grows and whenever the clinical form changes.
Appetite and nutrition should also be monitored closely. A kitten that continues to refuse food may require anti-nausea treatment, assisted nutrition or hospital care. Prolonged inadequate food intake can create additional complications, including hepatic lipidosis in cats.
Abdominal fluid does not usually need to be repeatedly drained if it is not compromising breathing or circulation. Pleural fluid causing respiratory distress may require urgent removal. As antiviral therapy begins working, fever and appetite may improve within days, while abdominal enlargement and laboratory abnormalities can take longer to resolve.
How Is Dry FIP Treated?
Dry or non-effusive FIP is treated with antiviral medication in the same way as wet FIP, but diagnosis and response assessment can be more difficult. Because there is little or no free fluid to sample or monitor, treatment decisions rely more heavily on organ lesions, blood results, imaging and the cat’s clinical progress.
Oral GS-441524 is commonly used when the cat can swallow medication and intestinal absorption is considered reliable. Remdesivir may be selected initially when the cat is critically ill, cannot take tablets or has severe gastrointestinal disease. Once the cat stabilises, a veterinarian may transition from injectable remdesivir to oral GS-441524.
Dry FIP can involve the liver, kidneys, intestines, lymph nodes or other tissues. Supportive treatment should therefore be based on the affected organs rather than applied identically to every cat. A cat with jaundice or persistent anorexia, for example, may need nutritional intervention because prolonged food refusal can also lead to hepatic lipidosis.
Response may be less visually obvious than in wet FIP. Fever and appetite may improve within days, while enlarged lymph nodes, organ lesions, anaemia, high globulin and a low A/G ratio may take weeks to normalise. Repeat blood tests, accurate weight measurements and follow-up ultrasound examinations are therefore important.
Corticosteroids do not eliminate the virus and should not replace antiviral therapy. They may occasionally be used for severe inflammatory or immune-mediated complications, but unnecessary or prolonged immunosuppression can make response assessment more difficult. Their use should be decided by the attending veterinarian.
A lack of improvement does not always mean GS-441524 is ineffective. Possible explanations include an incorrect diagnosis, poor drug quality, inadequate absorption, underdosing after weight gain, hidden ocular or neurological involvement or irreversible organ damage. The treatment plan and diagnosis should be reassessed rather than simply continuing an unchanged protocol.
How Are Neurological and Ocular FIP Treated?
Neurological and ocular FIP require effective antiviral concentrations within areas that many medications penetrate poorly. The blood–brain and blood–eye barriers can limit drug exposure, so these forms generally require a more intensive GS-441524 or remdesivir protocol than uncomplicated wet or dry FIP.
Neurological signs may include an unsteady gait, hind-limb weakness, tremors, head tilt, abnormal eye movements, behavioural changes, seizures or paralysis. Because tremors in cats can also result from poisoning, hypoglycaemia and other neurological diseases, these signs should not automatically be attributed to FIP without further assessment.
Published protocols commonly use higher antiviral exposure and may divide the daily oral dose into two administrations to maintain steadier concentrations. However, the correct milligram dose depends on the product’s formulation, bioavailability and verified concentration. Doses associated with older injectable products cannot be transferred directly to every modern oral preparation.
Neurological improvement may begin during the first weeks, but balance disorders, weakness or other deficits can take longer to resolve than fever and appetite loss. Anticonvulsants, assisted feeding, bladder care, physiotherapy and protection from falls may be required while the antiviral controls the underlying infection.
Ocular FIP may cause uveitis, cloudiness, unequal pupils, iris colour changes, bleeding inside the eye or impaired vision. These findings can resemble other causes of a red or painful eye in cats, making a detailed ophthalmic examination important.
Eye drops may control pain, inflammation or secondary complications, but they cannot treat systemic FIP by themselves. Systemic antiviral treatment remains essential. Corticosteroid eye drops must not be used until a veterinarian has excluded corneal ulceration and determined that they are appropriate.
Cats with neurological or ocular disease should be monitored closely throughout treatment and after therapy ends. If these signs appear while a cat is already being treated for wet or dry FIP, the antiviral plan may need to be intensified promptly because emerging nervous-system or eye involvement can precede relapse. Clinical studies have documented successful treatment even in cats with neurological or ocular involvement, although these cases require particularly careful dosing and follow-up.
What Is Remdesivir, and When Is It Used for FIP?
Remdesivir is an antiviral prodrug that is converted inside the body into an active compound closely related to GS-441524. It inhibits viral RNA replication and can be used against the feline coronavirus responsible for FIP in cats.
Remdesivir is most often considered when a cat is too unwell to swallow or reliably absorb oral medication. Intravenous administration can be useful during initial hospital treatment for cats with severe weakness, persistent vomiting, dehydration or neurological disease. Once the cat becomes stable and begins eating, treatment may be transitioned to oral GS-441524.
Subcutaneous remdesivir is another possible route, but injections can be painful and may cause inflammation, crusting or sores at the injection site. Intravenous treatment avoids repeated subcutaneous irritation but requires venous access and appropriate clinical monitoring. The route should be selected according to the cat’s condition and available veterinary facilities.
Remdesivir and GS-441524 are closely related, but their doses are not numerically interchangeable. Route of administration, formulation and conversion within the body affect the amount required. Owners should not attempt to calculate a GS-441524 dose from a remdesivir dose or administer leftover human medication.
In a clinical study involving parenteral remdesivir with or without transition to oral GS-441524, 24 of the 25 cats that survived the first 48 hours remained alive at six months. Fever, effusions and presenting signs generally improved during the first half of treatment, while globulin levels and body weight were more useful for later monitoring.
Remdesivir is licensed as a human medicine rather than a veterinary FIP product in many countries. Whether it can be prescribed for an individual cat depends on national veterinary prescribing rules. Access should therefore be arranged by a veterinarian rather than through informal sellers or medication left over from human treatment.
Are Molnupiravir and Other Antiviral Drugs Used for FIP?
Molnupiravir is another nucleoside analogue antiviral that interferes with viral replication by introducing errors into newly produced viral RNA. Evidence shows that it can be effective against FIP, but it is generally considered an alternative or rescue option rather than automatically replacing GS-441524 as the preferred first-line treatment.
Molnupiravir may be considered when GS-441524 or remdesivir cannot be obtained, when a cat does not respond adequately or when FIP returns after treatment. Before changing drugs, the veterinarian should investigate incorrect diagnosis, unreliable medication, poor absorption, weight-related underdosing and previously unrecognised ocular or neurological disease.
A prospective clinical trial treated ten cats with effusive FIP using oral molnupiravir. Eight cats survived and were in remission at 16 weeks; the two non-survivors died within the first 24 hours of treatment. Although the results were encouraging, the study was small, and larger trials are needed to define the safest protocols.
Possible concerns include changes in white blood cell counts, liver enzyme elevations and the drug’s potential effects on genetic material. Complete blood counts and serum biochemistry should be monitored. Cats receiving treatment who remain anorexic or develop jaundice also require evaluation for liver complications, including hepatic lipidosis.
Human molnupiravir capsules should not be divided or reformulated at home. Powder exposure should be avoided, particularly by anyone who is pregnant or may become pregnant. Veterinary dosing and pharmacy preparation are necessary because human capsule strengths may be unsuitable for accurate feline treatment.
Other antiviral agents, including GC376 and newer nucleoside or protease inhibitors, are being studied. Some have produced promising results, but evidence, product quality and legal availability remain inconsistent. They should not be combined with GS-441524 or substituted for it solely on the advice of an online seller. Rescue or combination treatment should be supervised by a veterinarian familiar with current FIP protocols.
How Can Cat Owners Access Safe and Legal FIP Treatment?
Access to GS-441524 and remdesivir depends on the country because neither drug has the same veterinary approval status worldwide. The safest first step is to contact a veterinarian familiar with current FIP treatment and ask which licensed, compounded or legally imported options are available for the individual cat.
In the United States, GS-441524 is not FDA-approved as an animal drug. However, the FDA has stated that it does not intend to enforce certain approval requirements when patient-specific GS-441524 is compounded under the conditions described in Guidance for Industry # 256. A veterinary prescription is still required, and compounded preparations do not carry the same FDA verification as an approved veterinary medicine.
Veterinarian-prescribed GS-441524 has consequently become available through regulated compounding channels in the United States.
In the United Kingdom, Australia and some European countries, veterinarians may access GS-441524, remdesivir or pharmacy-prepared formulations through national prescribing systems. Regulations differ considerably, and a product legally available in one country may remain unapproved or restricted in another. Rules may also change as new evidence and products become available.
Owners should ask the veterinarian or dispensing pharmacy for:
The exact active ingredient and concentration
The prescribed dose and administration schedule
The name and contact details of the dispensing pharmacy
Batch, expiry and storage information
Instructions for missed or vomited doses
A monitoring and follow-up schedule
Advice about what to do if the cat deteriorates
Time matters, but urgency should not eliminate basic safety checks. While access is being arranged, the cat may require hospitalisation, nutritional support, oxygen, anti-nausea treatment or other stabilisation. Supportive care cannot cure FIP, but it may keep a critically ill cat stable enough for antiviral therapy to work.
Why Are Unregulated FIP Medications Risky?
For years, desperate owners had little choice but to search informal online groups for GS-441524. These networks helped some cats when regulated treatment was unavailable, but unregulated products can vary significantly in identity, strength, purity, sterility and stability.
A label may state a particular concentration even though the product contains less—or occasionally more—active ingredient. Too little medication can cause treatment failure or relapse, while excessive or contaminated medication can create avoidable adverse effects. Inconsistent concentrations also make accurate veterinary dose adjustments impossible.
Injectable products present additional risks. Poor sterility can cause abscesses or systemic infection, while unsuitable pH, solvents or impurities may produce severe pain, inflammation, ulceration and tissue damage. Oral products may have inconsistent absorption or contain excipients that have not been assessed for use in cats.
Warning signs of an unreliable product include:
No pharmacy or identifiable manufacturer
No batch number, expiry date or storage instructions
No verified concentration
Handwritten or incomplete labelling
Medication repackaged into unmarked containers
Claims that blood tests or veterinary supervision are unnecessary
Pressure to combine several antivirals without clinical justification
Promises of a guaranteed cure
Owners who have already obtained an unregulated product should not be shamed or advised to hide its use. They should show the packaging, concentration and dosing information to their veterinarian. This allows the cat’s response and laboratory results to be interpreted more safely and may reveal whether a change to a regulated preparation is needed.
Switching between products can also be problematic because equal volumes or tablet numbers may not deliver equal amounts of active drug. Any transition should be calculated using the confirmed milligram strength, the cat’s current weight and the clinical form of FIP being treated.
How Long Does FIP Treatment Usually Last?
The traditional antiviral treatment period for FIP is 84 days, or 12 weeks. This duration was established through early GS-441524 studies and remains a commonly used approach, particularly when treatment response cannot be assessed through an intensive monitoring programme.
Treatment duration should not be determined by the calendar alone. Clinical signs, body weight, blood results, imaging findings and the presence of neurological or ocular disease must also be considered. Cats with complicated FIP, a delayed response or persistent abnormalities may require a longer or modified course.
New evidence suggests that some carefully selected cats with wet FIP may recover with shorter treatment. A prospective controlled study compared 42 and 84 days of pharmacy-prepared oral GS-441524 in cats with effusive FIP. Thirty-eight of the 40 enrolled cats recovered, with comparable outcomes in both groups.
This does not mean owners should automatically stop treatment after 42 days. The shortened protocol was used under veterinary supervision with confirmed medication, defined dosing and structured follow-up. Its findings cannot be safely transferred to unregulated products, cats with uncertain diagnoses or neurological and ocular FIP.
Before treatment is stopped, the cat should ideally have:
Normal temperature, appetite and activity
Stable or increasing body weight
Resolution of abdominal or chest fluid
No active eye or neurological abnormalities
Improving or normalised blood results
No new organ lesions or clinical deterioration
A veterinarian’s assessment that remission has been achieved
PCR negativity alone is not required to define recovery and should not overrule the overall clinical picture. Conversely, a cat that looks healthy but still has important laboratory or neurological abnormalities may not be ready to stop treatment.
A post-treatment observation period of approximately 12 weeks is commonly recommended. During this time, weight, appetite, energy and any previous neurological or ocular signs should be monitored. Owners can find broader information about the disease course in VetSaglik’s guide to FIP in cats.
How Quickly Should a Cat Respond to FIP Treatment?
Many cats show their first response within 24–72 hours of starting an effective antiviral. Fever may fall, appetite may return and the cat may become more alert. In one clinical series, improvement was observed in responding cats after a median of two days.
A typical response pattern may look like this:
Time after treatment begins | Possible improvements |
1–3 days | Lower fever, improved appetite and increased alertness |
3–7 days | More activity, better hydration and gradual weight gain |
1–2 weeks | Reduction in abdominal or chest fluid |
2–6 weeks | Improvement in anaemia, globulin, bilirubin and A/G ratio |
Later treatment period | Continued weight gain and resolution of remaining abnormalities |
This timeline is approximate. Neurological deficits, ocular inflammation and organ lesions may improve more slowly than fever or appetite. Some cats require supportive care even when the antiviral is beginning to control the infection.
A kitten should be weighed at least weekly because rapid growth can cause the original dose to become inadequate. Increasing appetite and weight are positive signs, but the administered milligram amount must be recalculated whenever body weight changes.
If the cat remains completely anorexic, the risk extends beyond FIP itself. Cats that do not eat can develop hepatic lipidosis, while repeated vomiting in cats can lead to dehydration and unreliable absorption of oral medication.
A cat that shows no meaningful improvement within approximately three to five days, or deteriorates at any point, should be reassessed promptly. Possible explanations include:
Incorrect or incomplete diagnosis
Inadequate dose for the cat’s weight or FIP form
Poor-quality or incorrectly labelled medication
Vomiting or reduced intestinal absorption
Unrecognised ocular or neurological involvement
Severe secondary infection or organ failure
A complication requiring hospital treatment
Open-mouth breathing, collapse, seizures, profound weakness, hypothermia or inability to swallow requires emergency care immediately; owners should not wait several days to judge the antiviral response.
Frequently Asked Questions About FIP Treatment in Cats
Can a Cat Be Completely Cured of FIP?
Yes. GS-441524, remdesivir and certain alternative antivirals can produce sustained remission in many cats. Successfully treated cats may return to normal health and live for years without FIP-related problems. However, outcome depends on diagnostic accuracy, disease severity, medication quality, correct dosing and appropriate monitoring.
Is GS-441524 the Preferred Treatment for FIP?
Oral GS-441524 is currently considered a preferred first-line antiviral in many contemporary FIP protocols. Remdesivir may be more appropriate initially when a cat is critically ill, cannot swallow medication or cannot reliably absorb an oral product.
How Soon Should FIP Treatment Begin?
Treatment should begin as soon as the diagnosis is adequately supported and safe medication can be obtained. Wet FIP can deteriorate quickly, especially when fluid affects breathing. Appropriate diagnostic samples should be collected first when possible, but a critically ill cat should not be left untreated while waiting unnecessarily for every result.
How Quickly Should GS-441524 Start Working?
Many responding cats show reduced fever, improved appetite or increased activity within one to three days. Effusions and laboratory abnormalities usually take longer to resolve. Failure to improve within approximately three to five days warrants reassessment of the diagnosis, dose, formulation and possible complications.
Does Abdominal Fluid Disappear With FIP Treatment?
In responding cats, abdominal fluid is often gradually reabsorbed after antiviral treatment begins and may resolve within approximately two weeks. Abdominal effusion is not normally drained repeatedly unless it is causing a specific clinical problem. Pleural fluid restricting breathing may require urgent removal.
How Long Does GS-441524 Treatment Last?
A conventional course lasts 84 days. Evidence indicates that selected cats with effusive FIP may recover with a veterinarian-supervised 42-day protocol, but owners should not shorten treatment independently. Neurological, ocular, relapsing or slowly responding cases may require a more intensive or extended plan.
Why Must a Kitten Be Weighed During Treatment?
Recovering kittens can gain weight rapidly. If the administered milligram amount remains unchanged, the dose per kilogram gradually falls and may become inadequate. Weight should therefore be measured accurately every one to two weeks, or more frequently when growth is rapid.
What Should I Do If My Cat Vomits an Antiviral Dose?
Do not automatically repeat the full dose because some medication may already have been absorbed. Record how long after administration vomiting occurred and contact the prescribing veterinarian. Repeated vomiting in cats may require anti-nausea treatment, hydration support or a different administration route.
Can Supplements or Corticosteroids Cure FIP?
No. Vitamins, immune supplements, nutritional products and corticosteroids do not stop feline coronavirus replication. Supportive treatments may help manage complications, but an effective antiviral is required to treat the underlying infection. Corticosteroids should only be used for a specific indication under veterinary supervision.
Is FIP Treatment Safe?
GS-441524 is generally well tolerated when an accurately formulated product is administered appropriately. Possible abnormalities include gastrointestinal signs, injection-site reactions and transient changes in liver enzymes or blood cells. Unregulated products create additional risks because their concentration, purity and sterility may be uncertain.
Can FIP Return After Treatment?
Yes, although many cats remain in long-term remission. Relapse may occur after inadequate antiviral exposure, poor absorption, treatment ending too soon or unrecognised neurological or ocular disease. Recurrent fever, appetite loss, weight loss, effusion, eye inflammation or neurological signs require prompt reassessment.
Is a Cat With FIP Contagious to Other Cats?
FIP itself is generally not transmitted directly as FIP from one cat to another. The underlying feline coronavirus is contagious, particularly through faecal contamination and shared litter boxes. Other cats in the home should not be assumed to have FIP solely because they were exposed to the affected cat. More information is available in VetSaglik’s general guide to FIP in cats.
When Is FIP an Emergency?
Open-mouth breathing, severe respiratory effort, collapse, seizures, inability to stand, hypothermia, profound weakness, repeated vomiting or inability to eat or drink requires immediate veterinary care. A cat that stops eating is also at risk of developing hepatic lipidosis.
Sources
Official Source | Open Link |
European Advisory Board on Cat Diseases – FIP Guideline | |
U.S. Food and Drug Administration – Position on Compounded GS-441524 for FIP | |
Cornell University College of Veterinary Medicine – GS-441524 Treatment for FIP | |
UC Davis School of Veterinary Medicine – FIP Antiviral Research | |
NIH PubMed – Efficacy and Safety of GS-441524 for Naturally Occurring FIP | |
NIH PubMed – Remdesivir With or Without Oral GS-441524 for FIP | |
NIH PubMed – Remdesivir and GS-441524 Treatment in 32 Cats | |
NIH PubMed – 42-Day Versus 84-Day Oral GS-441524 Treatment | |
NIH PubMed – Molnupiravir for Effusive FIP | |
NIH PubMed – Long-Term Follow-up After Oral GS-441524 Treatment | |
NIH PubMed – Systematic Review of GS-441524 Efficacy | |
Mersin Vetlife Veterinary Clinic |